Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms

Current Medical Research and Opinion

Volumn 33, Issue 7, 2017, Pages 1349-1351

  Allen, Andrew P ^a,b   Clarke, Gerard ^a,b   Cryan, John F ^a,b   Quigley, Eamonn M M ^c   Dinan, Timothy G ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL STRAIN; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; COMMENSAL; DRUG EFFICACY; EDITORIAL; HUMAN; INTESTINE FLORA; IRRITABLE COLON; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRAIN IDENTIFICATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; BIFIDOBACTERIUM; SENSITIVITY AND SPECIFICITY;

BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM SUBSPECIES INFANTIS; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85019551354     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1322571     Document Type: Editorial

References (29)

1. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation:systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547–61
2. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome:a systematic review. Gut 2010;59:325–32
3. Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome:a systematic review. Am J Gastroenterol 2010;104:1033–49
4. Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria:a meta-analysis. BMC Gastroenterol 2016;16:62
5. Yuan F, Ni H, Asche CV, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome:a meta-analysis. Curr Med Res Opin 2017;1–17
6. Charbonneau D, Gibb RD, Quigley EM., Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 2013;4:201–11
7. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome:symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–51
8. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581–90
9. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687–96
10. Cappello C, Tremolaterra F, Pascariello A, et al. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS):effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis 2013;28:349–58
11. Lewis ZT, Shani G, Masarweh CF, et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 2016;79:445–52
12. Altmann F, Kosma P, O’Callaghan A, et al. Genome analysis and characterisation of the exopolysaccharide produced by Bifidobacterium longum subsp. longum 35624™. PLoS One 2016;11:e0162983
13. Hill C, Scott K, Klaenhammer T, et al. Probiotic nomenclature matters. Gut Microbes 2016;7:1–2
14. Mazurak N, Broelz E, Storr M, et al. Probiotic therapy of the irritable bowel syndrome:why is the evidence still poor and what can be done about it? J Neurogastroenterol Motil 2015;21:471–85
15. Whelan K., Editorial:the importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol 2014;109:1563–5
16. Allen AP, Dinan TG, Clarke G, et al. A psychology of the human brain-gut-microbiome axis. Soc Personal Psychol Compass. 2017;11:e12309
17. Camilleri M., Probiotics and irritable bowel syndrome:rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 2006;40:264–9
18. Wall R, Cryan JF, Ross RP, et al. Bacterial neuroactive compounds produced by psychobiotics. In:Lyte M, Cryan JF, editors. Microbial endocrinology:The microbiota-gut-brain axis in health and disease. New York:Springer; 2014. p 221–39
19. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657–64
20. Desbonnet L, Garrett L, Clarke G, et al. The probiotic Bifidobacteria infantis:an assessment of potential antidepressant properties in the rat. J Psychiatr Res 2008;43:164–74
21. Rahimi R, Nikfar S, Abdollahi M., Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome:a meta-analysis of randomized controlled trials. Arch Med Sci 2008;4:71–6
22. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015;161:264–76
23. Moloney RD, O’Mahony SM, Dinan TG, et al. Stress-induced visceral pain:toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatr 2015;16:15
24. Allen AP, Hutch W, Borre YE, et al. Bifidobacterium longum 1714 as a translational psychobiotic:modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatr 2016;6:e939
25. Savignac HM, Kiely B, Dinan TG, et al. Bifidobacteria exert strain‐specific effects on stress‐related behavior and physiology in BALB/c mice. Neurogastroenterol Motil 2014;26:1615–27
26. Savignac HM, Tramullas M, Kiely B, et al. Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav Brain Res 2015;287:59–72
27. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci 2011;108:16050–5
28. Kelly JR, Allen AP, Temko A, et al. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain Behav Immun 2016;61:50–9
29. Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS):a systematic review and meta-analysis. Eur Arch Psychiatr Clin Neurosci 2014;264:651–60